Researchers conducted a post-hoc analysis of a prospective, multicenter cohort of 516 patients with bloodstream infection due to Enterobacteriaceae or BSI-E. The BSI-E was initially treated with ertapenem or antipseudomonal β-lactams.
They examined factors associated with early de-escalation as well as the effect of associated with early de-escalation and late de-escalation on 30-day all-cause mortality. Antibiotic de-escalation typically means reducing the spectrum of administered antibiotics by discontinuing certain drugs or switching to an agent with a narrower spectrum, according to a 2015 study in Current Opinion in Infectious Diseases.
The current study shows that early de-escalation was performed in 241 patients, late de-escalation in 98 and no de-escalation in 180.
Researchers found variables independently associated with a lower probability of early de-escalation were multidrug-resistant isolates and nosocomial infection empirically treated with imipenem or meropenem.
Additionally, they found early de-escalation was not associated with increased risk of mortality and late de-escalation was not associated with mortality. De-escalation was not associated with clinical failure nor did it affect length of hospital stay.
More articles on healthcare quality:
Safety concerns remain as surgeons explore robot-assisted breast cancer operations
Nursing in 2018: 10 most-read stories
How Sentara hospitals used copper to drop infection rates
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
